Despite the presence of several factors as positive predictors of HFimpHF, i.e., female gender, age < 55 years, de novo HF associated with hypertension and atrial fibrillation, sodium–glucose cotransporter-2 (SGLT2) inhibitors, and beta-blockers, and those as negative predictors, such as NYHA class III/IV, anemia, coronary artery disease (CAD), and type 2 diabetes mellitus (T2DM), the role of conventionally used circulating biomarkers in the management of HFimpHF is still not clearly investigated [10,11]. Here, SLC5A2 is linked to coronary artery disorder.